UBS reiterated a 'Buy' rating on the stock of Elevance Health, Inc. on August 8, 2025.
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UBS reiterated a 'Buy' rating on the stock of Elevance Health, Inc. on August 8, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
UBS
Swiss multinational investment bank and financial services company
-
Elevance Health, Inc.
American healthcare company
Nothing else this week.
Related events
- Banks including Royal Bank of Canada, Morgan Stanley, Bank of America, and DZ Bank issued rating updates on UBS stock.
- UBS upgraded Lockheed Martin to 'Buy' status, while MarketWatch and MarketBeat reported on L3Harris stock and AI initiatives.
- UBS surveyed wealthy American investors on October 15, 2026.
- UBS downgraded SSR Mining Inc. stock rating on July 29, 2025.
- CLSA retained an 'outperform' rating on M&M, and UBS acquired a stake in an Indian company.
Coverage
Newest first; wire copies grouped- Insider MonkeyUBS Affirms Elevance Health’s (ELV) ‘Buy’ Rating on Earning Stability and Growth Prospects Elevance Health, Inc. (NYSE:ELV) is one of the best depressed stocks to buy in 2025. On July 28, UBS reitera